|
Forth Photonics is a high-tech medical device company in Biophotonics, Spectral Imaging and in vivo
Optical Molecular Imaging focusing on the development of automated, cost-effective devices for the
non-invasive optical detection, screening and guided therapeutics of cancerous and pre-cancerous lesions.
The Company has developed a proprietary technology platform that has the potential to address a number
of diseases affecting millions of people worldwide and costing billions of dollars to healthcare systems.
The strategy of Forth Photonics is to focus on the development of innovative optical diagnostic devices
and screening tools, with high impact on healthcare practice.
The first product of this technology platform that Forth Photonics recently introduced to the market is called
DySISTM and focuses on the non-invasive in vivo diagnosis of cervical cancer. The product is CE-Marked with
intended use as a novel imaging technology replacing conventional colposcopes. DySIS provides quantitative
diagnostic information for detecting and grading cervical neoplasia in vivo and guidance for biopsy sampling
and treatment.
These advantages argue strongly for the adoption of DySIS in colposcopy as the most advanced colposcopic
imaging technology available today. DySIS is expected to revolutionize current colposcopic practice by
providing a user-independent high baseline performance in colposcopy.
The FORTH Photonics group is comprised of two companies:
- FORTH Photonics Ltd, based in Edinburgh, UK, and
- FORTH Photonics Hellas SA based in Athens, Greece
Forth-Photonics conducts innovative research work in the fields of Biophotonics, Spectral Imaging and in vivo
Optical Molecular Imaging. The company's proprietary "Dynamic Spectral Imaging", platform technology emerges
as the most efficient technology for the non-invasive diagnosis of precancerous tissue lesions. Long-term
pioneering laboratory and clinical investigations have confirmed the diagnostic potential of the Dynamic
Spectral Imaging technology in numerous medical fields including gynecology, dermatology, surgery etc.
The company has successfully implemented the Dynamic Spectral Imaging technology to address the problem of
detecting and mapping of early stage cervical precancer. To this end, the DySIS imaging device has been
developed up to the level of a final CE-Marked product, the performance of which has been evaluated in
multi-site clinical trials in UK and Greece. Clinical data collected have clearly demonstrated the superior
performance of DySIS when compared to traditional or competing methods and results of the clinical evaluation
have been presented to international conferences. These results highlight the device's potential to replace
existing diagnostic procedures as an integrated, cost-effective technology, capable of providing diagnosis,
screening and guidance for surgical treatment of cervical cancers and pre-cancers, even at the
gynaecologist's office. The company has launched this product to European markets and plans to obtain
FDA clearance on 2008.
In addition, Forth-Photonics has produced innovative technologies in the field of spectral imaging.
Initially developed as a research tool, "Hyperspectral Imaging" currently constitutes the company's
second technology platform. The company has developed, produced and globally commercialized the MuSIS
TM Hyperspectral (HS) and Multispectral (MS) camera systems. The MuSIS TM platform technology provides
the basis for current and future product development in the fields of remote sensing and non-destructive
analysis, with emphasis to the biomedical applications.
The company collaborates with several companies and research laboratories in Greece, the EU and the USA.
It is also interested in collaborations with developers of CCD, CMOS camera electronics, developers of
in vivo and in vitro biomarkers and distributors of the company's products in EU and USA.
|
